Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Exagen (XGN) Other financing activities (2020 - 2025)

Exagen filings provide 3 years of Other financing activities readings, the most recent being $199000.0 for Q3 2025.

On a quarterly basis, Other financing activities changed N/A to $199000.0 in Q3 2025 year-over-year; TTM through Mar 2026 was $804000.0, a 1136.92% increase, with the full-year FY2025 number at $869000.0, changed N/A from a year prior.
Other financing activities hit $199000.0 in Q3 2025 for Exagen, down from $605000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $4.2 million in Q1 2021 to a low of $65000.0 in Q1 2025.